Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements (Details)

v3.21.2
Collaboration and License Agreements (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Mar. 10, 2020
USD ($)
Jul. 31, 2021
USD ($)
shares
Apr. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Milestone
Country
Jun. 30, 2021
USD ($)
Milestone
Country
BioSense License and Assignments Agreement [Member]          
Collaboration and License Agreement [Abstract]          
Upfront payment received $ 1,650,000        
Milestone payment achieved for performance obligation, recorded as collaboration revenue       $ 100,000  
Milestone payments received     $ 50,000   $ 0
Maximum amount of payments receivable for development, regulatory and commercial milestones       $ 84,500,000 84,500,000
BioSense License and Assignments Agreement [Member] | Subsequent Event [Member]          
Collaboration and License Agreement [Abstract]          
Milestone payments received   $ 50,000      
BioSense License and Assignments Agreement [Member] | Rexahn [Member]          
Collaboration and License Agreement [Abstract]          
Upfront payment received $ 1,550,000        
Processa License Agreement [Member]          
Collaboration and License Agreement [Abstract]          
Milestone payments received         $ 0
Number of times sales milestone payments | Milestone       1 1
Percentage of milestone payments eligible to receive on sub-license agreement       32.00% 32.00%
Number of countries | Country       1 1
Milestone period to administer drug clinical trial of licensed product on first patient         3 years
Milestone period to administer drug clinical trial of licensed product on first patient for second indication         5 years
Period of opportunity to cure breach of agreement         120 days
Period of prior written notice to be served for termination of agreements         120 days
Processa License Agreement [Member] | Subsequent Event [Member]          
Collaboration and License Agreement [Abstract]          
Upfront payment received   $ 200,000      
Upfront payment received in common shares (in shares) | shares   44,689